Inhibition of signaling downstream of beta‐2 adrenoceptor by propranolol in prostate cancer cells

BACKGROUND: There is accumulating evidence that propranolol, an antagonist of beta‐1 and beta‐2 adrenoreceptors, extends survival of patients with prostate cancer; yet it is not known whether propranolol inhibits beta‐adrenergic signaling in prostate cancer cells, or systemic effects of propranolol...

Descripción completa

Detalles Bibliográficos
Autores principales: Alaskar, Aljoharah, Abdulraqeb Ali, Amaal, Hassan, Sazzad, Shinwari, Zakia, Alaiya, Ayodele, von Holzen, Urs, Miller, Lance, Kulik, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100053/
https://www.ncbi.nlm.nih.gov/pubmed/36373761
http://dx.doi.org/10.1002/pros.24455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100053/
https://www.ncbi.nlm.nih.gov/pubmed/36373761
http://dx.doi.org/10.1002/pros.24455

Ejemplares similares